Evidence map›Paper›PMID 29766378›Full record

Trial reportClinical oral investigations2019

2-Methacryloyloxyethyl phosphorylcholine (MPC)-polymer suppresses an increase of oral bacteria: a single-blind, crossover clinical trial.

Natsumi Fujiwara, Hiromichi Yumoto, Koji Miyamoto, Katsuhiko Hirota, Hiromi Nakae, Saya Tanaka, Keiji Murakami, Yasusei Kudo, Kazumi Ozaki, Yoichiro Miyake

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical oral investigations, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Bio-inspired special wettability in oral antibacterial applications.Frontiers in bioengineering and biotechnology · 2022
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Natsumi FujiwaraDepartment of Oral Microbiology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan. nfujiwara@tokushima-u.ac.jp.ORCID http://orcid.org/0000-0002-9020-9478
Hiromichi YumotoDepartment of Periodontology and Endodontology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Koji MiyamotoLife Science Products Division, NOF Corporation, 4-20-3 Ebisu, Shibuya-ku, Tokyo, 150-6019, Japan.
Katsuhiko HirotaDepartment of Oral Microbiology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Hiromi NakaeDepartment of Hygiene and Oral Health Science, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Saya TanakaSchool of Oral Health and Welfare, Tokushima University Faculty of Dentistry, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Keiji MurakamiDepartment of Oral Microbiology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Yasusei KudoDepartment of Oral Molecular Pathology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Kazumi OzakiDepartment of Oral Healthcare Promotion, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Yoichiro MiyakeDepartment of Oral Microbiology, Tokushima University Graduate School of Biomedical Sciences, 3-18-15 Kuramoto-cho, Tokushima, Tokushima, 770-8504, Japan.
Tokushima University · JPTokushima Bunri University · JPNOF Corporation (Japan) · JP

Funding

Japan Society for the Promotion of Science 16K21198
6 · The paper itself

Abstract

objectivesThe biocompatible 2-methacryloyloxyethyl phosphorylcholine (MPC)-polymers, which mimic a biomembrane, reduce protein adsorption and bacterial adhesion and inhibit cell attachment. The aim of this study is to clarify whether MPC-polymer can suppress the bacterial adherence in oral cavity by a crossover design. We also investigated the number of Fusobacterium nucleatum, which is the key bacterium forming dental plaque, in clinical samples. MATERIALS AND

methodsThis study was a randomized, placebo-controlled, single-blind, crossover study, with two treatment periods separated by a 2-week washout period. We conducted clinical trial with 20 healthy subjects to evaluate the effect of 5% MPC-polymer mouthwash after 5 h on oral microflora. PBS was used as a control. The bacterial number in the gargling sample before and after intervention was counted by an electronic bacterial counter and a culture method. DNA amounts of total bacteria and F. nucleatum were examined by q-PCR.

resultsThe numbers of total bacteria and oral streptcocci after 5 h of 5% MPC-polymer treatment significantly decreased, compared to the control group. Moreover, the DNA amounts of total bacteria and F. nucleatum significantly decreased by 5% MPC-polymer mouthwash.

conclusionsWe suggest that MPC-polymer coating in the oral cavity may suppress the oral bacterial adherence. CLINICAL RELEVANCE: MPC-polymer can be a potent compound for the control of oral microflora to prevent oral infection.

Indexed as

AdultBacterial AdhesionBacterial LoadCross-Over StudiesDental PlaqueFemaleFusobacterium nucleatumHumansMaleMethacrylatesMouthwashesPhosphorylcholinePolymerase Chain ReactionPolymersSingle-Blind MethodStreptococcus mutans2-methacryloyloxyethyl phosphorylcholineMethacrylatesMouthwashesPhosphorylcholinePolymers2-Methacryloyloxyethyl phosphorylcholineClinical studyFusobacterium nucleatumOral bacteriaOral infection

Identifiers

PMID29766378
PMCPMC7736026
OpenAlexW2804624552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.